An observational study in Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture, sponsored by Desmond Tutu HIV Foundation. Completed at 1 site in South Africa. Open to participants aged 13 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Desmond Tutu HIV Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 10th largest by enrollment of the 11 observational ones that give a count, is one of 6 that started in 2020, is one of 11 observational ones, and was the 43rd registered.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
Browse Tuberculosis, Pulmonary studies →10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:
North-West University, South Africa · Sites in South Africa
Ages 18–45
Global Alliance for TB Drug Development · Sites in South Africa, Tanzania
Ages 18–65
Gates Medical Research Institute · Sites in South Africa
Ages 18–65
Thirty Respiratory Limited · Sites in South Africa
Ages 18–65
TASK Applied Science · Sites in South Africa
Ages 18–65
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.
This study: 13 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 57 · Phase 3 11
First in 2003; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is below the median of 300 across 83 observational studies indexed under Tuberculosis, Pulmonary.
Median enrollment 122 across the 67 interventional studies, 900 across the 11 observational. Of the 57 that completed or were terminated, 31 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 78 have an industry lead sponsor. The 10 most frequent:
Desmond Tutu HIV Foundation is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Desmond Tutu HIV Foundation has 1 study filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
6 of the studies in Tuberculosis, Pulmonary with a site in South Africa that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tuberculosis (TB) is transmitted in bioaerosols containing Mycobacterium tuberculosis (Mtb). Mtb-containing bioaerosols are likely related to host infectiousness and central to ongoing TB transmission. No routine diagnostic assay exists to measure Mtb in bioaerosols. Furthermore, published studies of Mtb in bioaerosol samples, have been limited to individuals with sputum-positive pulmonary TB. Currently TB diagnosis is based on clinical symptoms and sputum laboratory findings. However, approximately half of all patients commencing TB treatment are sputum negative resulting in a high proportion of presumptive treatments. We therefore propose to use a sensitive sampling protocol to investigate the prevalence of Mtb-containing bioaerosols in both sputum-positive and sputum-negative TB suspects.
Our pragmatic, parallel-group design is aimed at identifying viable Mtb in bioaerosols produced by individuals attending a TB clinic in Cape Town, South Africa. Bioaerosol sampling will be performed on all eligible individuals presenting with symptoms indicative of TB and repeated at 14 days if initially positive for viable Mtb. Participants will be classified into three distinct groups based on the National TB Control Program (NTBCP) criteria: Group A, TB notification with sputum-based laboratory confirmation; Group B, TB notification with empiric diagnosis; and Group C, individuals not notified. Group C individuals with detectable Mtb bioaerosol will be monitored until resolution of clinical and laboratory status. Collection of bioaerosol specimens will be via two consecutive sampling modalities: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect sampling following passive respiratory activity and environmental sampling. microscopy. Mtb genomes and mycobacterial and host lipids will be detected using droplet digital PCR and mass spectrometry analyses, respectively. The primary objective is to determine the prevalence of Mtb bioaerosols in all TB clinic attendees and in each of the mutually exclusive groups A, B and C. Secondary objectives are to investigate differences in prevalence of Mtb bioaerosol by HIV status, current isoniazid preventive therapy (IPT) use and pre and post initiation of anti-TB chemotherapy.
Consecutive patients with respiratory and/or constitutional symptoms suggestive of pulmonary TB who self-present to two TB clinics in high density peri-urban settlements in Cape Town, South Africa will be offered recruitment to the study
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.
Diagnostic Test: Bioaerosol Sampling
Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.
Diagnostic Test: Bioaerosol Sampling
Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.
Diagnostic Test: Bioaerosol Sampling
Cyclone collection of exhaled bioaerosol
Primary Aim
The difference in prevalence proportions of Mtb-containing bioaerosol in sputum positive and sputum negative pulmonary TB cases (Groups A \& B)
Time frame: 12 months
Secondary Aim (1)
The difference in numbers of viable MTB organisms in bioaerosols per liter of air sampled and per nano-liter of bioaerosol particulate volume collected in both sputum positive and sputum negative pulmonary TB cases (Groups A \& B).
Time frame: 12 months
Exploratory Aim (1)
The prevalence of MTB containing bioaerosols in TB suspects not diagnosed with clinical TB (Group C)
Time frame: 12 months
Exploratory Aim (2)
The difference in prevalence and numbers of viable MTB in subjects receiving and not receiving IPT prophylaxis.
Time frame: 12 months
Exploratory Aim (3)
The difference in prevalence and numbers of viable MTB in subjects with and without HIV-infection.
Time frame: 12 months
Exploratory Aim (4)
The difference in prevalence and numbers of viable MTB in subjects before and after TB therapy.
Time frame: 12 months
Exploratory Aim (5)
The difference in numbers of viable MTB in bioaerosol collected by direct and indirect sampling.
Time frame: 12 months
Exploratory Aim (6)
The ratio of MTB genomes (ddPCR) to viable MTB organisms (DMN-tre-positive) in MTB containing bioaerosol
Time frame: 12 months
Exploratory Aim (7)
Which MTB lipids are present in MTB containing bioaerosol
Time frame: 12 months
Plan to share: Yes — The outcomes of the analysis in addition to the unprocessed data will be submitted for publication in open-source peer-reviewed journals and presented at international conferences.
Supporting information: Study protocol, Statistical analysis plan
Ran from May 2020 to primary completion in May 2022, 24 months.
Of 45 observational studies under Tuberculosis, Pulmonary, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Desmond Tutu HIV Foundation